Molecular and cellular effects of gold nanoparticles treatment in experimental diabetic myopathy

Aseel Al-Shwaheen; Alaa A A Aljabali; Ghada Alomari; Mazhar Al Zoubi; Walhan Alshaer; Bahaa Al-Trad; Murtaza M Tambuwala

doi:10.1016/j.heliyon.2022.e10358

Molecular and cellular effects of gold nanoparticles treatment in experimental diabetic myopathy

Aseel Al-Shwaheen, Alaa A A Aljabali, Ghada Alomari, Mazhar Al Zoubi, Walhan Alshaer, Bahaa Al-Trad, Murtaza M Tambuwala

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

103 Downloads (Pure)

Abstract

This study aims to address the effects of gold nanoparticles (AuNPs) on diabetic myopathy in streptozotocin (STZ)-induced diabetic rats. Adult male rats were separated into three groups (n = 15): non-diabetic control (ND), diabetic (D), and diabetic treated with AuNPs (2.5 mg/kg, D + AuNPs) intraperitoneally for 4 weeks. A single injection of 50 mg/kg STZ was used to induce diabetes. Treatment with AuNPs lowered blood glucose levels. Skeletal muscle mRNA expression of two muscle-specific E3 ubiquitin-ligases enzymes, F-box-only protein 32 (FBXO32) and muscle RING-finger protein-1 (MuRF1) were upregulated in the D group. Diabetic rats showed significant increases in the skeletal muscle expression levels of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), and a decrease in glucose transporter 4 (GLUT4) expression. Superoxide dismutase (SOD) activity decreased and malondialdehyde (MDA) level increased in skeletal muscles of D group. Compared to the D group, expression levels of FBXO32, MuRF1, PAI-1 TNF-α, and TGF-β1 were decreased in the D + AuNPs group, and mRNA of GLUT4 increased. Furthermore, in D + AuNPs group, skeletal muscle MDA levels decreased while SOD activity increased. In experimental models, AuNPs can ameliorate muscle atrophy by reducing hyperglycemia, inflammation, and oxidative stress, and by suppressing the ubiquitin-proteasome proteolytic process.

Original language	English
Article number	e10358
Pages (from-to)	1-8
Number of pages	8
Journal	Heliyon
Volume	8
Issue number	9
Early online date	21 Aug 2022
DOIs	https://doi.org/10.1016/j.heliyon.2022.e10358
Publication status	Published (in print/issue) - 30 Sept 2022

Bibliographical note

Funding Information:
This work was supported by the Deans of Scientific Research and Graduate studies at Yarmouk University Grant number 46/2021.

Publisher Copyright:
© 2022 The Author(s)

Keywords

Nanomedicine
Diabetes mellitus
Gold nanoparticles
Skeletal muscle
Diabetic myopathy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.heliyon.2022.e10358

PIIS2405844022016462Final published version, 1.31 MBLicence: CC BY

Cite this

@article{d03a1ac913314924b611500a216bf3ac,

title = "Molecular and cellular effects of gold nanoparticles treatment in experimental diabetic myopathy",

abstract = "This study aims to address the effects of gold nanoparticles (AuNPs) on diabetic myopathy in streptozotocin (STZ)-induced diabetic rats. Adult male rats were separated into three groups (n = 15): non-diabetic control (ND), diabetic (D), and diabetic treated with AuNPs (2.5 mg/kg, D + AuNPs) intraperitoneally for 4 weeks. A single injection of 50 mg/kg STZ was used to induce diabetes. Treatment with AuNPs lowered blood glucose levels. Skeletal muscle mRNA expression of two muscle-specific E3 ubiquitin-ligases enzymes, F-box-only protein 32 (FBXO32) and muscle RING-finger protein-1 (MuRF1) were upregulated in the D group. Diabetic rats showed significant increases in the skeletal muscle expression levels of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), and a decrease in glucose transporter 4 (GLUT4) expression. Superoxide dismutase (SOD) activity decreased and malondialdehyde (MDA) level increased in skeletal muscles of D group. Compared to the D group, expression levels of FBXO32, MuRF1, PAI-1 TNF-α, and TGF-β1 were decreased in the D + AuNPs group, and mRNA of GLUT4 increased. Furthermore, in D + AuNPs group, skeletal muscle MDA levels decreased while SOD activity increased. In experimental models, AuNPs can ameliorate muscle atrophy by reducing hyperglycemia, inflammation, and oxidative stress, and by suppressing the ubiquitin-proteasome proteolytic process. ",

keywords = "Nanomedicine, Diabetes mellitus, Gold nanoparticles, Skeletal muscle, Diabetic myopathy",

author = "Aseel Al-Shwaheen and Aljabali, {Alaa A A} and Ghada Alomari and {Al Zoubi}, Mazhar and Walhan Alshaer and Bahaa Al-Trad and Tambuwala, {Murtaza M}",

note = "Funding Information: This work was supported by the Deans of Scientific Research and Graduate studies at Yarmouk University Grant number 46/2021. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = sep,

day = "30",

doi = "10.1016/j.heliyon.2022.e10358",

language = "English",

volume = "8",

pages = "1--8",

journal = "Heliyon",

issn = "2405-8440",

publisher = "Elsevier BV",

number = "9",

}

TY - JOUR

T1 - Molecular and cellular effects of gold nanoparticles treatment in experimental diabetic myopathy

AU - Al-Shwaheen, Aseel

AU - Aljabali, Alaa A A

AU - Alomari, Ghada

AU - Al Zoubi, Mazhar

AU - Alshaer, Walhan

AU - Al-Trad, Bahaa

AU - Tambuwala, Murtaza M

PY - 2022/9/30

Y1 - 2022/9/30

N2 - This study aims to address the effects of gold nanoparticles (AuNPs) on diabetic myopathy in streptozotocin (STZ)-induced diabetic rats. Adult male rats were separated into three groups (n = 15): non-diabetic control (ND), diabetic (D), and diabetic treated with AuNPs (2.5 mg/kg, D + AuNPs) intraperitoneally for 4 weeks. A single injection of 50 mg/kg STZ was used to induce diabetes. Treatment with AuNPs lowered blood glucose levels. Skeletal muscle mRNA expression of two muscle-specific E3 ubiquitin-ligases enzymes, F-box-only protein 32 (FBXO32) and muscle RING-finger protein-1 (MuRF1) were upregulated in the D group. Diabetic rats showed significant increases in the skeletal muscle expression levels of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), and a decrease in glucose transporter 4 (GLUT4) expression. Superoxide dismutase (SOD) activity decreased and malondialdehyde (MDA) level increased in skeletal muscles of D group. Compared to the D group, expression levels of FBXO32, MuRF1, PAI-1 TNF-α, and TGF-β1 were decreased in the D + AuNPs group, and mRNA of GLUT4 increased. Furthermore, in D + AuNPs group, skeletal muscle MDA levels decreased while SOD activity increased. In experimental models, AuNPs can ameliorate muscle atrophy by reducing hyperglycemia, inflammation, and oxidative stress, and by suppressing the ubiquitin-proteasome proteolytic process.

AB - This study aims to address the effects of gold nanoparticles (AuNPs) on diabetic myopathy in streptozotocin (STZ)-induced diabetic rats. Adult male rats were separated into three groups (n = 15): non-diabetic control (ND), diabetic (D), and diabetic treated with AuNPs (2.5 mg/kg, D + AuNPs) intraperitoneally for 4 weeks. A single injection of 50 mg/kg STZ was used to induce diabetes. Treatment with AuNPs lowered blood glucose levels. Skeletal muscle mRNA expression of two muscle-specific E3 ubiquitin-ligases enzymes, F-box-only protein 32 (FBXO32) and muscle RING-finger protein-1 (MuRF1) were upregulated in the D group. Diabetic rats showed significant increases in the skeletal muscle expression levels of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), and a decrease in glucose transporter 4 (GLUT4) expression. Superoxide dismutase (SOD) activity decreased and malondialdehyde (MDA) level increased in skeletal muscles of D group. Compared to the D group, expression levels of FBXO32, MuRF1, PAI-1 TNF-α, and TGF-β1 were decreased in the D + AuNPs group, and mRNA of GLUT4 increased. Furthermore, in D + AuNPs group, skeletal muscle MDA levels decreased while SOD activity increased. In experimental models, AuNPs can ameliorate muscle atrophy by reducing hyperglycemia, inflammation, and oxidative stress, and by suppressing the ubiquitin-proteasome proteolytic process.

KW - Nanomedicine

KW - Diabetes mellitus

KW - Gold nanoparticles

KW - Skeletal muscle

KW - Diabetic myopathy

UR - http://www.scopus.com/inward/record.url?scp=85137108756&partnerID=8YFLogxK

U2 - 10.1016/j.heliyon.2022.e10358

DO - 10.1016/j.heliyon.2022.e10358

M3 - Article

C2 - 36060470

SN - 2405-8440

VL - 8

SP - 1

EP - 8

JO - Heliyon

JF - Heliyon

IS - 9

M1 - e10358

ER -

Molecular and cellular effects of gold nanoparticles treatment in experimental diabetic myopathy

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this